1. Home
  2. News
  3. Acrux Limited
  4. Launch of Dapsone 5%, Gel in the United States
More Acrux Limited news
Acrux LimitedASX: ACR

Launch of Dapsone 5%, Gel in the United States

Apr 2, 2024 at 9:54 PM EDT · Issued by Acrux Limited

Filed with ASX · Apr 2, 2024 at 9:54 PM EDT · 1 page · English

Summary by 6ix AI

This topical prescription product is used to treat acne vulgaris and is part of Acrux's commercial pipeline. CEO Michael Kotsanis expressed excitement about this launch and future regulatory approvals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/launch-of-dapsone-5percent-gel-in-the-united-states

Acrux Limited on 6ix

Story so far

  • 4th FDA ANDA approval received - Dapsone Gel, 5%Jun 7, 2023
  • Launch of prilocaine and lidocaine cream in United StatesDec 21, 2022

Earlier from Acrux

  • Investor Presentation Half Year AccountsFeb 27, 2024
  • Appendix 4D and Half Year AccountsFeb 27, 2024
  • Appendix 4C and Activities StatementJan 30, 2024
  • Address of Chair and CEO to AGMNov 28, 2023
  • Acrux receives $2.88m R&D Tax Incentive Rebate for FY23Nov 7, 2023

Later from Acrux

  • Acrux presentation at Hidden Gems in Lifesciences ForumJun 12, 2024
  • RDTI funding facility securedJun 27, 2024
  • Acrux presentation to Bioshares, 18th Biotech SummitJul 14, 2024
  • Quarterly Activities Report and Appendix 4C - June 2024Jul 25, 2024
  • FDA Approval received for Dapsone Gel, 7.5%Aug 26, 2024
All Acrux news releases↗

Follow Acrux into a list and get an email when it puts out news.

Follow Acrux
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer